相关临床试验
344
38 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1956
进行中（未招募）
15
4.4%
已完成
185
53.8%
Enrolling By Invitation
4
1.2%
尚未招募
19
5.5%
招募中
51
14.8%
终止
24
7.0%
Unknown
31
9.0%
撤回
15
4.4%
暂无批准数据
- A new Landmark Perspective in Science marks the 50th anniversary of Robert C. Gallo's 1976 discovery of a human T-cell growth factor later named interleukin-2 (IL-2). - The discovery enabled long-term culture of human T cells, leading to identification of the first human retroviruses HTLV-1 and HTLV-2 and establishing human retrovirology. - The same capability proved critical to characterizing HIV as the cause of AIDS and to developing the HIV blood test, improving global blood supply safety. - IL-2 also underpinned cellular immunotherapy advances including tumor-infiltrating lymphocyte therapy and CAR-T cell therapy, with scientific exchange continuing in Venice in 2027.
- A University of South Florida expedition to Antarctica studied a sea squirt whose bacterium produces a compound that selectively kills melanoma cells without harming normal human cells. - The selectivity is considered critical for drug development, as researchers aim to treat the disease without harming the patient. - More than half of FDA-approved drugs originate from natural sources, and this discovery represents early-stage research that could eventually lead to new melanoma therapies. - Melanoma causes an estimated 57,000 deaths annually worldwide, a figure projected to rise to 96,000 by 2040.
- Florida becomes the first state to offer comprehensive newborn genetic screening through the Sunshine Genetics Pilot Program, providing free genetic sequencing to identify serious but treatable conditions before symptoms appear. - The initiative receives $7.5 million in state funding plus an additional $2 million from Florida State University, establishing the Institute for Pediatric Rare Diseases as the program's central hub. - The Sunshine Genetics Consortium unites Florida's top universities including FSU, UF, UM, USF, and FIU with hospitals and biotech companies to accelerate research and improve access to treatments for rare childhood diseases. - The program aims to end the "Diagnostic Odyssey" that families endure when seeking answers about rare diseases, with early diagnosis enabling proactive care and better outcomes for affected children.
- NeuroEM Therapeutics has closed initial rounds totaling $1.33 million of a $5 million Series A equity raise led by BlueLake.vc to commercialize its Transcranial Electromagnetic Treatment (TEMT-RF) technology. - The company's innovative approach uses radio frequencies delivered through a lightweight cap worn twice daily to target cognitive decline and restore brain function in Alzheimer's patients. - NeuroEM received the first FDA Breakthrough Device status for treating Alzheimer's disease and has demonstrated safety and cognitive enhancement in early clinical studies. - The funding will support continued progress toward commercialization of the drug-free treatment, which aims to prevent and treat cognitive decline caused by aging and neurodegenerative diseases.
- New Phase 3 RISE-PD study data reveals CREXONT (carbidopa/levodopa extended-release) significantly improved sleep quality in Parkinson's disease patients compared to immediate-release formulations, with a mean difference of -2.35 in PDSS-2 scores (p<0.0001). - Patients treated with CREXONT were significantly more likely to wake up in an "On" state compared to those on immediate-release carbidopa/levodopa, addressing a critical need as sleep disturbances affect up to 80% of Parkinson's patients. - The novel formulation combines immediate-release granules for rapid onset with extended-release pellets for sustained effect, potentially offering comprehensive symptom management throughout both day and night.
- Phase 3 LIBERTY-CSU CUPID trials demonstrate dupilumab's effectiveness in reducing itch and urticaria activity in patients unresponsive to H1-antihistamines. - Clinical benefits of dupilumab were consistent across all BMI ranges, including patients in obese categories, providing important efficacy data for diverse patient populations. - FDA review of dupilumab for chronic spontaneous urticaria is underway with a target action date of April 18, 2025, potentially offering a new treatment option for resistant cases.
- Leading hospitals across North America are actively engaged in clinical trials to find effective treatments for trigeminal neuralgia, a condition causing severe facial pain. - Institutions like the University of Minnesota, Toronto Western Hospital, UCSF Medical Center, Kaizen Brain Center, and the University of South Florida are conducting these trials. - These trials aim to improve patients' quality of life by exploring innovative approaches to managing this challenging neurological disorder. - Many of these institutions initiated their first investigations into trigeminal neuralgia in 2022, marking a significant push for new treatment strategies.
